

# Reem Saleh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6363592/publications.pdf>

Version: 2024-02-01

33  
papers

1,449  
citations

471371

17  
h-index

395590

33  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1879  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
2	Lag3: From Bench to Bedside. Cancer Treatment and Research, 2022, 183, 185-199.	0.2	7
3	Transcriptomic Profiling of Circulating HLA-DR <sup>+</sup> Myeloid Cells, Compared with HLA-DR <sup>+</sup> Myeloid Antigen-presenting Cells. Immunological Investigations, 2021, 50, 952-963.	1.0	2
4	Differential gene expression of tumor-infiltrating CD33 <sup>+</sup> myeloid cells in advanced- versus early-stage colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 803-815.	2.0	15
5	T <sup>H</sup> 1 cell responses and therapies against SARS-CoV-2 infection. Immunology, 2021, 162, 30-43.	2.0	159
6	Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 2103-2121.	2.0	23
7	Transcriptome of CD8 <sup>+</sup> tumor-infiltrating T cells: a link between diabetes and colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 2625-2638.	2.0	3
8	Transcriptome of Tumor-Infiltrating T Cells in Colorectal Cancer Patients Uncovered a Unique Gene Signature in CD4 <sup>+</sup> T Cells Associated with Poor Disease-Specific Survival. Vaccines, 2021, 9, 334.	2.1	5
9	Role of circular RNAs in colorectal tumor microenvironment. Biomedicine and Pharmacotherapy, 2021, 137, 111351.	2.5	10
10	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in Cancer Biology, 2020, 65, 13-27.	4.3	170
11	Epigenetic regulation of immune checkpoints and T <sup>H</sup> 1 cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics, 2020, 12, 1871-1882.	1.0	11
12	Exosomes: Biological Carriers and Promising Tools for Cancer Immunotherapy. Vaccines, 2020, 8, 390.	2.1	5
13	FoxP3 <sup>+</sup> T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Letters, 2020, 490, 174-185.	3.2	169
14	Differential gene expression of tumor-infiltrating CD4 <sup>+</sup> T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. OncoImmunology, 2020, 9, 1825178.	2.1	6
15	Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. Expert Opinion on Therapeutic Targets, 2020, 24, 1251-1262.	1.5	16
16	Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients. Frontiers in Oncology, 2020, 10, 1530.	1.3	7
17	Differential gene expression of tumor-infiltrating CD8 <sup>+</sup> T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. , 2020, 8, e001294.		25
18	RNA-Seq Analysis of Colorectal Tumor-Infiltrating Myeloid-Derived Suppressor Cell Subsets Revealed Gene Signatures of Poor Prognosis. Frontiers in Oncology, 2020, 10, 604906.	1.3	8

#	ARTICLE	IF	CITATIONS
19	DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF- $\beta$ 2 genes in HLA-DR <sup>+</sup> myeloid cells, compared with HLA-DR <sup>+</sup> antigen-presenting cells. <i>Epigenetics</i> , 2020, 15, 1275-1288.	1.3	21
20	Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1989-1999.	2.0	75
21	Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression. <i>Frontiers in Immunology</i> , 2020, 11, 1469.	2.2	58
22	Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants. <i>Genes</i> , 2020, 11, 703.	1.0	14
23	Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer. <i>Clinical Epigenetics</i> , 2020, 12, 13.	1.8	52
24	PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer. <i>Cancers</i> , 2019, 11, 1050.	1.7	50
25	Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4 <sup>+</sup> T Cells. <i>Vaccines</i> , 2019, 7, 149.	2.1	63
26	Treg-mediated acquired resistance to immune checkpoint inhibitors. <i>Cancer Letters</i> , 2019, 457, 168-179.	3.2	148
27	Cytokine-Induced Acute Inflammatory Monoarticular Arthritis. <i>Methods in Molecular Biology</i> , 2018, 1784, 215-223.	0.4	1
28	CCL17 blockade as a therapy for osteoarthritis pain and disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 62.	1.6	71
29	CSF-1 in Inflammatory and Arthritic Pain Development. <i>Journal of Immunology</i> , 2018, 201, 2042-2053.	0.4	22
30	TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17. <i>JCI Insight</i> , 2018, 3, .	2.3	36
31	G-CSF Receptor Blockade Ameliorates Arthritic Pain and Disease. <i>Journal of Immunology</i> , 2017, 198, 3565-3575.	0.4	28
32	Granulocyte macrophage colony-stimulating factor receptor $\beta$ expression and its targeting in antigen-induced arthritis and inflammation. <i>Arthritis Research and Therapy</i> , 2016, 18, 287.	1.6	38
33	Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation. <i>Journal of Clinical Investigation</i> , 2016, 126, 3453-3466.	3.9	129